Clavis/Clovis tumble as trial kills gemcitabine-rescue theory
This article was originally published in Scrip
Executive Summary
Both Clavis Pharma and Clovis Oncology were roundly punished on the stock markets today after revealing the unambiguous failure of their lipid-conjugated gemcitabine C0-101 (CP-4126) in metastatic pancreatic cancer. Norwegian Clavis saw its stock price fall by 86% to NOK1.24 by mid-afternoon, while Colorado-based Clovis's share was trading down 33.6% at $14.26 in mid-morning trading in the US.